Impact of the modulation of the intratumoral hypoxia on the improvement ofPD-1/PD-L1-based immune checkpoint blockade

Medicine & Life Sciences

1. Hypoxia 100%
2. Immunotherapy 34%
3. Immunosuppressive Agents 32%
4. Hypoxia-Inducible Factor 1 24%
5. Tumor Microenvironment 20%
6. Neoplasms 19%
7. Melanoma 16%
8. Therapeutic Uses 16%
9. Clinical Trials 12%
10. Breast Neoplasms 12%